Technology Sponsor

Microbial Biologics





About BioVectra:

BioVectra is a Contract Development and Manufacturing Organization (CDMO) that serves the top global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients (APIs). An innovative and reliable service partner with a strong regulatory history, we have over 50 years of experience specializing in:

· cGMP microbial fermentation
· Complex chemistry – high potency APIs
· Biologics
· Formulation development

The BioVectra team of 500+ highly skilled employees operate out of 5 cGMP facilities located in Atlantic Canada, with excellent proximity to eastern North American development entities. BioVectra’s scalable cGMP facilities include over 225,000 ft2 of manufacturing space, 118,000 L of chemical reactor space (20 L to 18,000 L), and 64,000 L of fermentation bioreactor capacity (30 L to 17,000 L). Their APIs have been used in therapeutics to treat cancer, kidney disease, cardiovascular disease, multiple sclerosis, and many other serious diseases.




How is BioVectra contributing to the future of healthcare?

BioVectra is building on their 50-year legacy to contribute to the future of healthcare. Their complex chemistry unit is experienced with the extraction, purification, and synthesis of high-value intermediates and active pharmaceutical ingredients. Their biomanufacturing unit focuses on microbial fermentation and the downstream

processing of biologics. In addition, BioVectra’s drug development activities focus on new chemical entities with complex active ingredients and challenging formulations.

The BioVectra team engages in product development in partnership with major pharmaceutical companies for the further advancement of drug products. The company is specifically focused on microbial fermentation processes, complex chemical synthesis, and complex IV and IM formulations. BioVectra’s expert team is also versed in manufacturing and development processes critical for the future of healthcare including antibody-drug conjugates, potent compounds, taxane chemistry, liposomal formulations, MPEG chemistry and conjugation, nanoparticles, depot formulations, and many other product classes and formulation methods.